Smithfield Trust Co Increases Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Smithfield Trust Co increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 41.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,510 shares of the biopharmaceutical company’s stock after buying an additional 440 shares during the quarter. Smithfield Trust Co’s holdings in Gilead Sciences were worth $127,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Thompson Siegel & Walmsley LLC raised its position in shares of Gilead Sciences by 65.2% in the third quarter. Thompson Siegel & Walmsley LLC now owns 111,305 shares of the biopharmaceutical company’s stock worth $9,332,000 after acquiring an additional 43,921 shares during the period. LPL Financial LLC raised its position in shares of Gilead Sciences by 7.4% in the third quarter. LPL Financial LLC now owns 1,137,381 shares of the biopharmaceutical company’s stock worth $95,358,000 after acquiring an additional 78,839 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Gilead Sciences by 38.2% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 764,520 shares of the biopharmaceutical company’s stock worth $64,097,000 after acquiring an additional 211,493 shares during the period. Cornerstone Advisors LLC raised its position in shares of Gilead Sciences by 6.0% in the third quarter. Cornerstone Advisors LLC now owns 68,400 shares of the biopharmaceutical company’s stock worth $5,735,000 after acquiring an additional 3,900 shares during the period. Finally, Citizens Financial Group Inc. RI raised its position in shares of Gilead Sciences by 5.6% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 6,321 shares of the biopharmaceutical company’s stock worth $530,000 after purchasing an additional 337 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GILD has been the subject of several research analyst reports. UBS Group upped their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research report on Thursday. Mizuho increased their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday. Oppenheimer increased their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $74.00 to $96.00 in a report on Monday, October 21st. Finally, Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a report on Monday. Twelve research analysts have rated the stock with a hold rating, eleven have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.41.

Gilead Sciences Price Performance

Shares of GILD opened at $89.84 on Friday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The firm’s fifty day simple moving average is $87.28 and its 200-day simple moving average is $76.61. The firm has a market capitalization of $111.96 billion, a price-to-earnings ratio of 998.22, a PEG ratio of 2.72 and a beta of 0.17. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period last year, the business earned $2.29 EPS. The company’s revenue was up 7.0% on a year-over-year basis. Equities analysts forecast that Gilead Sciences, Inc. will post 4.38 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.43%. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The trade was a 27.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 1.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,947 shares of company stock worth $4,968,674 in the last ninety days. 0.16% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.